fbpx
Subscribe
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Archive

EU approves expanded use of Spravato in depression – Janssen Pharma

Written by | 15 Feb 2021

The Janssen Pharmaceutical Companies of Johnson & Johnson announced that the European Commission (EC) has authorised the expanded use of Spravato (esketamine nasal spray)..

Most patients with COVID-19 suffer lasting effects

Written by | 15 Jan 2021

Most people hospitalised with COVID-19 have at least one symptom six months after falling ill, according to a follow-up study of people in Wuhan China.

One in four women with ADHD has attempted suicide

Written by | 5 Jan 2021

Attention Deficit Hyperactive Disorder (ADHD) can have negative consequences on mental health into adulthood.

Medical staff plagued by insomnia during pandemic

Written by | 25 Nov 2020

Article written by Gary Finnegan More than a third of medical staff suffered insomnia during the COVID-19 epidemic in China, according to a new study.

Balancing the response to covid-19

Written by | 18 Oct 2020

Article written by Christine Clark As politicians grapple with the idea of a lockdown or a more stringent lockdown GPs have called for an end to the ‘one-track’… read more.

Dozens of blood pressure drugs do not elevate risk of depression

Written by | 9 Oct 2020

Article written by Bruce Sylvester Dozens of the most widely used blood pressure medications show no tendency to elevate risk of depression, Danish researchers report.

Pesco-Mediterranean diet, intermittent fasting may lower heart disease risk

Written by | 7 Oct 2020

A Pesco-Mediterranean diet rich in plants, nuts, whole grains, extra-virgin olive oil, and fish and/or seafood is ideal for optimizing cardiovascular health, according to a cumulative review published… read more.

Hostility linked with higher risk of death after second heart attacks

Written by | 5 Oct 2020

Heart attack patients who are sarcastic or irritable could be putting their health at risk, according to research published today in the European Journal of Cardiovascular Nursing, a journal… read more.

Depression, but not anxiety, linked with inflammation and metabolic change

Written by | 4 Oct 2020

Anxiety and depression are often linked and assumed to be closely related, but now research has shown for the first time that depression and anxiety have different biochemical… read more.

Top-line results from the phase III CLARITY study evaluating pimavanserin for the adjunctive treatment of major depressive disorder.-Acadia Pharmaceuticals.

Written by | 23 Jul 2020

Acadia Pharmaceuticals Inc. announced top-line results from its 298 patient Phase III CLARITY study which combined two identical, double-blind, placebo-controlled studies evaluating the efficacy, safety and tolerability of… read more.

Soleno Therapeutics announces top-line results from phase III trial of DCCR for treatment of Prader-Willi syndrome.

Written by | 14 Jun 2020

Soleno Therapeutics, Inc. announced top-line results from the Company’s Phase III trial, DESTINY PWS (C601), evaluating once-daily Diazoxide Choline Controlled Release (DCCR) tablets for patients with Prader-Willi Syndrome… read more.

STRIDE-1 Phase III Trial of AXS 05 meets key secondary endpoints in depression.- Axsome Therapeutics

Written by | 1 Apr 2020

Axsome Therapeutics announced that AXS 05 (bupropion + dextromethorphan) met key secondary endpoints in the STRIDE-1 trial by rapidly and statistically significantly improving symptoms of depression on the… read more.

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.

Subscribe

You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.